Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abexinostat with Palbociclib and Fulvestrant in ER+ Breast/Gyn Cancer
NCT04498520Phase 1Withdrawn
- Sponsor
- Alessa Therapeutics
- Start
- Mar 2021
- Primary completion
- Jun 2025
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of abexinostat in breast cancer, endometrial cancer (EC), ovarian cancer and 2 more, sponsored by Alessa Therapeutics. Primary endpoints: Dose limiting toxicities, Maximum tolerated dose and 1 more. Planned start Mar 2021; status: withdrawn.
02
Drugs
abexinostat
03
Conditions
breast cancerendometrial cancer (EC)ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT04498520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04498520.